Abstract
Pneumococcal disease is associated with high mortality and significant burden in older adults. No universal pneumococcal vaccination program is included in Brazil’s national immunization program (NIP) for older adults. This study aims to evaluate the cost-effectiveness of introducing a single-dose 23-valent polysaccharide vaccine (PPSV23) against pneumococcal disease for adults 60 years versus no vaccination (NV) from the Brazilian public payer perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
